Ozempic and similar weight-loss drugs linked to 30% lower breast cancer risk
New research presented at the ASCO Annual Meeting suggests that GLP-1 weight-loss drugs like Ozempic may be linked to a 30% lower risk of developing breast cancer. While the findings are observational, they indicate a potential new use for these medications.
Why it matters
This could significantly impact public health strategies and cancer prevention research for patients using diabetes and weight-loss medications.
Popular medications such as Ozempic, Wegovy, Mounjaro, and Zepbound may offer an unexpected benefit beyond helping people lose weight and manage diabetes. New research involving more than 110,000 women found that those taking GLP-1 drugs, a category that includes semaglutide-based medications like Ozempic and Wegovy, were significantly less likely to develop breast cancer.
Scientific reporting that includes necessary caveats about observational study limitations.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in